Clarametyx to Present on Its Anti-Biofilm Technology Platform During Antimicrobial Pipeline Session At IDWeek 2024
COLUMBUS, Ohio – October 9, 2024 – Clarametyx Biosciences Inc. (“Clarametyx”), a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, has been selected to present its novel technology platform during IDWeek 2024 as part of an Antimicrobial Pipeline Session on Friday, October 18, 2024, starting at 8 am PT (Petree C Hall).
“We believe our technology represents a novel opportunity to combat chronic infections while reducing the urgent global threat of antimicrobial resistance. We look forward to connecting with the world’s leading infectious disease experts during IDWeek to present clinical data supporting our technology and gain insights that can inform our continued progress,” said David Richards, Chief Executive Officer.
During the session, Clarametyx will share development progress and initial clinical data on its lead program, CMTX-101, a novel immune-enabling antibody therapy. CMTX-101 is designed to precisely and rapidly destroy the universal underlying structure of bacterial biofilms, with the goal of undermining bacterial defenses and enabling more effective antibiotic and immune interventions. CMTX-101 is currently being investigated in a Phase 1b/2a clinical trial as an adjunct to standard of care for the treatment of chronic infections associated with cystic fibrosis.
About CMTX-101
CMTX-101 is an immune-enabling antibody therapy designed to precisely and rapidly destroy the universal underlying structure of bacterial biofilms to undermine extracellular bacterial defenses and enable more effective antibiotic and immune intervention. Because the target is universally present across bacteria, the technology can be employed to treat a range of bacterial infections, many of which are characterized by the presence of multiple types of bacteria. CMTX-101 is intended to be administered concomitantly with a wide range of standard-of-care antibiotics that target both Gram-negative and Gram-positive bacteria. The goal of treatment is to dramatically improve the effectiveness of antibiotic therapies and innate immune system effectors, improving the time to resolution of the infection and reducing the need for repeated courses of antibiotics.
About Clarametyx Biosciences
Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a dynamic pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms, with a near-term focus on challenging respiratory infections. For more information, visit us on the web or on LinkedIn.
Media Contact:
Kellie Hotz
khotz@clarametyx.com
+1-703-887-6242
# # #